CF
LJPC

Centaurus Financial’s La Jolla Pharmaceutical Company LJPC Stock Holding History

Centaurus Financial’s Portfolio LJPC Stock Details LJPC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q3 		– Sell
-400
Closed -$12K – 2527
2018
Q2 		$12K Buy
+400
New +$12.3K ﹤0.01% 1502

Other funds holding LJPC

PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return
SCM
Scopia Capital Management New York $146M AUM 25.93% 1-Year Est. Return
BC
Broadfin Capital New York $747M AUM 100.56% 1-Year Est. Return
SAM
Sectoral Asset Management Montreal, Quebec, Canada $121M AUM 73.47% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return

Centaurus Financial's LJPC Position: Q3 2018 in Review

Centaurus Financial sold out of La Jolla Pharmaceutical Company (LJPC) in Q3 2018, closing a stake of 400 shares — an estimated $12K sold.

Centaurus Financial first reported a position in LJPC in Q2 2018 and held it in 1 quarter. The position peaked at $12K in Q2 2018. 78 funds tracked by Wall St. Rank hold LJPC as of Q3 2018.

  • Centaurus Financial reported no remaining La Jolla Pharmaceutical Company position as of Q3 2018 after selling out during the quarter.
  • Centaurus Financial sold 400 La Jolla Pharmaceutical Company shares in Q3 2018, an estimated $12K.
  • Centaurus Financial first reported a position in La Jolla Pharmaceutical Company in Q2 2018 and held it in 1 quarter.
  • Centaurus Financial's La Jolla Pharmaceutical Company position peaked at $12K in Q2 2018.
  • 78 funds tracked by Wall St. Rank held La Jolla Pharmaceutical Company as of Q3 2018.

Based on Centaurus Financial's 13F filing for Q3 2018, filed 5 Nov 2018.